Complete response of deep neutrophilic dermatosis associated with myelodysplastic syndrome to 5-azacytidine.
Cutaneous manifestations of myelodysplastic syndromes (MDS) may predict disease progression and a poorer prognosis. We describe a patient in whom a deep neutrophilic dermatosis preceded evolution of disease from refractory anaemia to RAEB (refractory anaemia with excess blasts) and resolved completely on treating the disease with 5-azacytidine. The dermatological response was accompanied by complete bone marrow remission and trilineage haematological improvement. We suggest that 5-azacytidine should be considered in the treatment of immune mediated cutaneous manifestations of MDS.
Raj
K
K
Department of Haematological Medicine, King's College London and King's College Hospital, Denmark Hill, London, UK.
Ho
A
A
Creamer
J D
JD
du Vivier
A W P
AW
Salisbury
J R
JR
Mufti
G J
GJ
D000368:Aged; D000754:Anemia, Refractory, with Excess of Blasts / Q000150:complications; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D006257:Head; D006801:Humans; D008297:Male; D009333:Neck; D012074:Remission Induction; D012782:Shoulder; D012871:Skin Diseases / Q000188:drug therapy* / Q000209:etiology
D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine